Our study confirmed that the NAFLD-related inflammation occurred in our in vivo model, as demonstrated by the significantly increased levels of IL-18, TNF-α, IL-6, MCP-1, and IL-1β; these levels were reduced after treatment with EMPA. Here, IL18 is linked to metabolic dysfunction-associated steatotic liver disease.